Solute carrier family 5 member 2. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Dapagliflozin CHEMBL429910 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
✓ Both | 131 |
| Canagliflozin CHEMBL4594217 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Sotagliflozin CHEMBL3039507 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
✓ Both | 4 |
| Henagliflozin CHEMBL4297431 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Ertugliflozin CHEMBL1770248 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Empagliflozin CHEMBL2107830 |
Sodium/glucose cotransporter 2 inhibitor Inhibitor Small molecule |
✓ Both | — |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Cardiovascular disorder | 4 | Phase 3 |
| Diabetic kidney disease | 4 | Phase 3 |
| Hypertensive disorder | 4 | Phase 3 |
| Atrial fibrillation | 3 | Phase 3 |
| Heart failure | 3 | Phase 3 |
| COVID-19 | 2 | Phase 3 |
| Increased body weight | 2 | Phase 3 |
| Acute myocardial infarction | 2 | Phase 3 |
| Chronic kidney disease | 2 | Phase 3 |
| Hypertrophic cardiomyopathy | 2 | Phase 3 |
| COVID-19–associated multisystem inflammatory syndrome in children | 1 | Phase 3 |
| Cognitive impairment | 1 | Phase 3 |
| Hyperglycemia | 1 | Phase 3 |
| Hypoglycemia | 1 | Phase 3 |
| IgA glomerulonephritis | 1 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
